Patents Examined by Ginny Portner
-
Patent number: 9005954Abstract: The present invention relates to compositions and methods to identify novel bacteria and metabolites derived therefrom. More specifically, the invention describes a novel method to isolate bacteria producing metabolites of interest from environmental samples. Particularly, the invention discloses a method to select rare antibiotic producing bacteria. The invention can be used from any sample and allows the isolation of bacteria having e.g., pharmaceutical or agrochemical interest.Type: GrantFiled: January 18, 2010Date of Patent: April 14, 2015Assignees: Deinove, Centre National de la Recherche ScientifiqueInventors: Jean-Paul Leonetti, Stéphanie Texier
-
Patent number: 9006395Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide, is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: October 7, 2010Date of Patent: April 14, 2015Assignee: The Secretary of State for HealthInventors: Clifford Charles Shone, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8968749Abstract: The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Leishmania.Type: GrantFiled: May 27, 2014Date of Patent: March 3, 2015Assignee: Universidade Federal de Minas Gerais—UFMGInventors: Ana Paula Salles Moura Fernandes, Christiane De Freitas Abrantes, Eduardo Antonio Ferraz Coelho, Ricardo Tostes Gazzinelli
-
Patent number: 8968750Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.Type: GrantFiled: December 6, 2010Date of Patent: March 3, 2015Assignee: Ruprecht-Karls-Universität HeidelbergInventors: Ann-Kristin Mueller, Eva Morath
-
Patent number: 8962026Abstract: The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.Type: GrantFiled: September 25, 2009Date of Patent: February 24, 2015Assignee: The Regents of the University of MichiganInventors: James R. Baker, Jr., Mark R. Hemmila, Stewart C. Wang, Tarek Hamouda, John J. LiPuma, Jessica A. Knowlton, Paul E. Makidon, Luz P. Blanco, Jeffery V. Groom, II, Anna U. Bielinska
-
Patent number: 8946393Abstract: A method for diagnosing Lyme disease status in a mammal is provided. The method entails, in a biological sample obtained or derived from a mammal, determining antibodies to Borrelia burgdorferi (B. burgdorferi) outer surface proteins (Osp) OspA, OspC, and OspF. Based upon determining the OspA, OspC, and OspF antibodies, the mammal can be diagnosed as vaccinated, not vaccinated, infected or not infected with B. burgdorferi. Mammals that have early, intermediate or chronic B. burgdorferi infection can also be identified. The method is particularly suited for use with horses and dogs. Isolated or recombinant B. burgdorferi antigens and compositions that contain them are also provided.Type: GrantFiled: September 27, 2011Date of Patent: February 3, 2015Assignee: Cornell UniversityInventor: Bettina Wagner
-
Patent number: 8940309Abstract: The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.Type: GrantFiled: September 4, 2014Date of Patent: January 27, 2015Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: William Charles Ohnesorge, Isabelle Freiin Von Richthofen, Marika Christine Genzow, Martina Von Freyburg, Carola Kissel, Luc-Etienne Fabry, Knut Elbers, Kathleen Kwan Young Park
-
Patent number: 8940482Abstract: A cell based assay for detection for protease activity is disclosed. In the assay a cell is engineered to express a protease substrate with at least one label, preferably on its C-terminus. Cleavage of the substrate by the protease that recognizes it results in a C-terminal fragment and a N-terminal fragment, where the fragment having the label is subject to ubiquitin proteasome degradation. The assay measures the disappearance of the label due to degradation of the fragment to which it is attached. A cell free assay is also described for detection of protease activity. In the cell free assay, the protease substrate is expressed in a solution that includes the elements of the ubiquitin proteasome pathway for degradation of the fragment. The assay measures the disappearance of the label attached to the fragment that results from cleavage by the protease.Type: GrantFiled: June 13, 2011Date of Patent: January 27, 2015Assignee: Synaptic Research, LLCInventors: George A. Oyler, Yien Che Tsai
-
Patent number: 8932600Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.Type: GrantFiled: January 27, 2011Date of Patent: January 13, 2015Assignees: GlaxoSmithKline Biologicals S.A., Glaxo Group LimitedInventors: Normand Blais, James Brown, Anne-Marie Gelinas, Pascal Mettens, Dennis Murphy
-
Patent number: 8926980Abstract: Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents.Type: GrantFiled: July 11, 2012Date of Patent: January 6, 2015Assignee: Camas IncorporatedInventors: Bradley M Mitteness, Connie Phillips
-
Patent number: 8920816Abstract: A method is provided for treating a neuromuscular defect in a subject. One step of the method includes locating a target nerve. After locating the target nerve, a treatment probe is provided. The treatment probe includes an elongated body member having a proximal end portion and a distal end portion. The distal end portion includes an energy delivery mechanism for stimulating or ablating the target nerve, a monitoring mechanism, and a fluid aspiration/delivery mechanism. Next, the target nerve is verified as an appropriate target for ablation by stimulating and then monitoring the target nerve via the energy delivery mechanism and the monitoring mechanism, respectively. After verifying the target nerve, a tumescent fluid is injected into the tissue surrounding the target nerve. An electric current is then delivered to the energy delivery mechanism to substantially ablate the target nerve.Type: GrantFiled: July 29, 2013Date of Patent: December 30, 2014Assignee: The Cleveland Clinic FoundationInventor: Francis A. Papay
-
Patent number: 8921071Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.Type: GrantFiled: October 21, 2013Date of Patent: December 30, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Michael Otto, Stanislava Kocianova
-
Patent number: 8907060Abstract: The invention provides mutated Pseudomonas exotoxins (PE) that have reduced immunogenicity compared to PEs containing the native sequence. The PEs of the invention have one or more individual mutations of positions of the native sequence of PE that reduce antibody binding to one or more PE epitopes. Nucleic acids encoding the mutated PEs, chimeric molecules comprising them, compositions comprising the chimeric molecules and methods of using them, are also provided.Type: GrantFiled: July 25, 2006Date of Patent: December 9, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Masanori Onda, Satoshi Nagata, David Fitzgerald, Robert Kreitman, Byungkook Lee
-
Patent number: 8900597Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: August 19, 2013Date of Patent: December 2, 2014Assignee: Wyeth LLCInventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender Kumar Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Patent number: 8883166Abstract: Vaccines have been studied that comprise (a) D-T-Pw-HepB-Hib antigens and (b) one or more meningococcal conjugate antigens. A number of improvements and variations of these vaccines have been discovered. The vaccines can be prepared extemporaneously at the time of use by mixing together two components: (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a Hib conjugate and one or more meningococcal conjugates.Type: GrantFiled: March 16, 2006Date of Patent: November 11, 2014Assignee: Novartis AGInventors: Mario Contorni, Donatella Mannucci
-
Patent number: 8877201Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.Type: GrantFiled: October 23, 2008Date of Patent: November 4, 2014Assignee: Wake Forest University Health SciencesInventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
-
Patent number: 8871906Abstract: The invention provides mutated, cytotoxic forms of Pseudomonas exotoxin A (PE) comprising a furin cleavage sequence conjugated or fused directly to residues 395-613 of PE or variants of that sequence. These minimal forms of PE are smaller than previous cytotoxic forms of PE, reduce non-specific toxicity, and reduce immunogenicity due to domain II or domain Ib of PE. The invention further provides nucleic acids encoding said PEs, chimeric molecules containing them, and methods of use thereof.Type: GrantFiled: September 4, 2008Date of Patent: October 28, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, John Weldon, David FitzGerald
-
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
Patent number: 8865186Abstract: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.Type: GrantFiled: October 3, 2011Date of Patent: October 21, 2014Assignee: New York UniversityInventors: Konstantin Ichtchenko, Philip A. Band -
Patent number: 8865177Abstract: Methods for treating a pressure sore or for preventing development of a pressure sore by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a pressure sore or to a pressure point, or to the vicinity thereof.Type: GrantFiled: October 31, 2007Date of Patent: October 21, 2014Assignee: Allergan, Inc.Inventor: Eric R. First
-
Patent number: 8859235Abstract: A method for the manufacture of products by biotechnological methods in bacterial cell culture is disclosed as well as products obtained, the use of certain additives to the media used in the manufacture of said products in bacterial cell culture media, and the use of said additives in reducing the detrimental effects of radicals in the manufacture of the products, as well as aspects related to these invention embodiments. The manufacturing process or method comprises adding one or more radical scavenging and/or antioxidative additive preferably selected from the group consisting of sterically hindered nitroxyls, sterically hindered hydroxylamines, sterically hindered hydroxylamine salt compounds, sterically hindered amino compounds and sterically hindered N-hydrocarbyloxyamines, benzofuranone compounds, as obligatory component(s) to the medium used during biosynthesis.Type: GrantFiled: August 11, 2010Date of Patent: October 14, 2014Assignee: BASF SEInventors: Franz Kaufmann, Trine Hefsgaard Miller, Johannes Flothmann, Beate Winter, Andreas Hafner